Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
THG ( (GB:THG) ) just unveiled an update.
THG PLC reported its interim results for the first half of 2025, showing a return to revenue growth in the second quarter, driven by strategic changes in its beauty and nutrition divisions. The company completed a successful demerger of THG Ingenuity and disposed of Claremont Ingredients, which, along with refinancing, improved its net cash position. Despite a slight decline in overall group revenue, THG anticipates stronger performance in the second half, supported by increased brand partnerships and market share gains, particularly in the UK beauty sector and Myprotein’s expansion in offline retail and licensing.
The most recent analyst rating on (GB:THG) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on THG stock, see the GB:THG Stock Forecast page.
Spark’s Take on GB:THG Stock
According to Spark, TipRanks’ AI Analyst, GB:THG is a Neutral.
THG’s overall stock score is primarily impacted by its financial performance and valuation concerns. The company faces significant financial challenges, including declining revenues and high leverage. Technical analysis indicates bearish momentum, and the negative P/E ratio reflects ongoing losses. These factors collectively contribute to a cautious outlook for the stock.
To see Spark’s full report on GB:THG stock, click here.
More about THG
THG PLC operates in the e-commerce and technology sector, focusing on beauty and nutrition products. The company is known for its brands such as THG Beauty and Myprotein, and it has a strong market presence in the UK and Europe. THG also engages in strategic partnerships and brand licensing to expand its market reach.
Average Trading Volume: 4,827,632
Technical Sentiment Signal: Sell
Current Market Cap: £417.7M
Find detailed analytics on THG stock on TipRanks’ Stock Analysis page.